Remedium and Exothera Partner on Scale-Up and Demonstration Runs for AAV2-FGF18

Remedium Bio and Exothera S.A. reached an agreement for a collaboration to demonstrate the industrialization potential of Remedium’s AAV2-FGF18. Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for osteoarthritis.